Payment overview · 2025
General Payments
$3,576.40
101 reported records · 21 companies
Healthcare provider profile · identity verified
Simon Kwanmin Lee, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BURLINGAME, CA · NPI 1275532145
Verified facts
What the public records show
CMS Open Payments records show Simon Kwanmin Lee, M.D. received $3,576.40 in general payments during 2025 across 101 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Creon, Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Ozempic, Prolia, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $793.69 | 22.2% | 16 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $450.80 | 12.6% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $355.99 | 9.9% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $310.22 | 8.7% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $301.63 | 8.4% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $257.88 | 7.2% | 7 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $186.14 | 5.2% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $170.23 | 4.8% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $160.68 | 4.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $118.00 | 3.3% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $77.30 | 2.2% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $75.86 | 2.1% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.92 | 1.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $58.45 | 1.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $46.26 | 1.3% | 2 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $32.63 | 0.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.76 | 0.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $25.35 | 0.7% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $24.18 | 0.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.13 | 0.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.30 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,576.40 | 101 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $387.00 | 14 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $325.26 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $279.44 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $257.44 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $253.26 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $231.69 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $221.66 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $170.23 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $160.86 | 6 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $160.68 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $153.60 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $151.01 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $128.82 | 9 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $119.55 | 1 | 2025 |
Source payment records
|
|||||
| ANDEXXA Normalized: andexxa |
Biological | AstraZeneca Pharmaceuticals LP | $107.23 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $96.37 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $89.54 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $85.75 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $76.68 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $75.86 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $75.86 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $63.80 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $61.92 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $58.45 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $54.59 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $53.30 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $52.78 | 3 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $50.20 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $49.69 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $46.26 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.45 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $32.24 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $32.24 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $28.76 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $25.35 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 15 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 148 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 205 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 263 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 75 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 38 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 56 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 109 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
75 | 38 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
38 | 28 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
205 | 58 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
263 | 71 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
109 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
263 | 71 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
148 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
60 | 58 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1661 | 510 |
| Amlodipine Besylate | Amlodipine Besylate | 1350 | 405 |
| Losartan Potassium | Losartan Potassium | 1188 | 342 |
| Metformin Hcl | Metformin Hcl | 665 | 209 |
| Metoprolol Succinate | Metoprolol Succinate | 618 | 179 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 417 | 201 |
| Pantoprazole Sodium | Pantoprazole Sodium | 377 | 146 |
| Omeprazole | Omeprazole | 340 | 127 |
| Alendronate Sodium | Alendronate Sodium | 328 | 107 |
| Gabapentin | Gabapentin | 290 | 117 |
| Tamsulosin Hcl | Tamsulosin Hcl | 276 | 88 |
| Simvastatin | Simvastatin | 273 | 76 |
| Jardiance | Empagliflozin | 263 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 259 | 74 |
| Lisinopril | Lisinopril | 238 | 73 |
| Zolpidem Tartrate | Zolpidem Tartrate | 236 | 64 |
| Meloxicam | Meloxicam | 222 | 95 |
| Lovastatin | Lovastatin | 213 | 59 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 207 | 58 |
| Farxiga | Dapagliflozin Propanediol | 205 | 58 |
| Azithromycin | Azithromycin | 203 | 149 |
| Diclofenac Sodium | Diclofenac Sodium | 185 | 121 |
| Famotidine | Famotidine | 182 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 175 | 54 |
| Januvia | Sitagliptin Phosphate | 171 | 49 |
| Azelastine Hcl | Azelastine Hcl | 161 | 75 |
| Allopurinol | Allopurinol | 157 | 47 |
| Furosemide | Furosemide | 154 | 57 |
| Meclizine Hcl | Meclizine Hcl | 151 | 99 |
| Eliquis | Apixaban | 148 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 147 | 55 |
| Finasteride | Finasteride | 141 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 48 |
| Valsartan | Valsartan | 139 | 48 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 138 | 80 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 137 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 59 |
| Pioglitazone Hcl | Pioglitazone Hcl | 126 | 41 |
| Carvedilol | Carvedilol | 119 | 31 |
| Metformin Hcl Er | Metformin Hcl | 118 | 36 |
| Sertraline Hcl | Sertraline Hcl | 117 | 35 |
| Benazepril Hcl | Benazepril Hcl | 116 | 29 |
| Glipizide | Glipizide | 109 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 109 | 31 |
| Hydrocortisone | Hydrocortisone | 105 | 58 |
| Potassium Chloride | Potassium Chloride | 101 | 38 |
| Lorazepam | Lorazepam | 100 | 32 |
| Atenolol | Atenolol | 99 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 29 |
| Fenofibrate | Fenofibrate | 98 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 32 |
| Donepezil Hcl | Donepezil Hcl | 95 | 40 |
| Naproxen | Naproxen | 85 | 52 |
| Montelukast Sodium | Montelukast Sodium | 84 | 29 |
| Colchicine | Colchicine | 81 | 39 |
| Linzess | Linaclotide | 75 | 38 |
| Trazodone Hcl | Trazodone Hcl | 75 | 29 |
| Acarbose | Acarbose | 71 | 22 |
| Ibuprofen | Ibuprofen | 68 | 45 |
| Doxazosin Mesylate | Doxazosin Mesylate | 67 | 23 |
| Glimepiride | Glimepiride | 62 | 17 |
| Ezetimibe | Ezetimibe | 61 | 22 |
| Glipizide Er | Glipizide | 61 | 17 |
| Mupirocin | Mupirocin | 60 | 42 |
| Paxlovid | Nirmatrelvir/Ritonavir | 60 | 58 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 14 |
| Telmisartan | Telmisartan | 57 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 16 |
| Rybelsus | Semaglutide | 56 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 17 |
| Nitroglycerin | Nitroglycerin | 54 | 28 |
| Tradjenta | Linagliptin | 54 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 22 |
| Prednisone | Prednisone | 53 | 23 |
| Ozempic | Semaglutide | 51 | 14 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 50 | 12 |
| Loperamide | Loperamide Hcl | 48 | 29 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Fluocinonide | Fluocinonide | 47 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 39 |
| Amoxicillin | Amoxicillin | 43 | 30 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 43 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 42 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 19 |
| Nifedipine Er | Nifedipine | 39 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 12 |
| Prolia | Denosumab | 38 | 28 |
| Terazosin Hcl | Terazosin Hcl | 38 | 11 |
| Irbesartan | Irbesartan | 36 | 12 |
| Lidocaine | Lidocaine | 36 | 13 |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 12 |
| Ketoconazole | Ketoconazole | 34 | 18 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | 12 |
| Bumetanide | Bumetanide | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 31 | 12 |
| Spironolactone | Spironolactone | 31 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 30 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 22 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Baclofen | Baclofen | 28 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 23 |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Ofloxacin | Ofloxacin | 23 | 17 |
| Dutasteride | Dutasteride | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 21 | 11 |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Erythromycin | Erythromycin Base | 20 | 11 |
| Temazepam | Temazepam | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Entecavir | Entecavir | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | 13 |
| Nystop | Nystatin | 17 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | 11 |
| Nateglinide | Nateglinide | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Permethrin | Permethrin | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Triazolam | Triazolam | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Desloratadine | Desloratadine | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Cymbalta | Duloxetine Hcl | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | 12 |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Selenium Sulfide | Selenium Sulfide | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,576.40 · 101 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, ANDEXXA, AREXVY, BREZTRI, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, Fluad, Flucelvax, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, Kerendia, LINZESS, Livdelzi, M-M-R II, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error